Sevoflurane stimulated KRAS signalings

2023 Fiscal Year Final Research Report

• Project/Area Number: 19K18291
• Research Category: Grant-in-Aid for Early-Career Scientists
• Allocation Type: Multi-year Fund
• Review Section: Basic Section 55050:Anesthesiology-related
• Research Institution: Nagoya University
• Principal Investigator: Konishi Yuko 名古屋大学, 医学系研究科, 特任講師 (60771970)
• Project Period (FY): 2019-04-01 – 2024-03-31
• Keywords: セボフルラン / 原がん遺伝子

Outline of Final Research Achievements

In recent years, anesthesiologists and their groups have actively reported both basic and cohort studies to clarify whether the chance of recurrence and metastasis occurs during the peri-operative period under anesthesia. Our groups have studied the influence of sevoflurane, a volatile anesthetic, on cell survival through cell cycle arrest or induction of cell proliferation. In this study, I aimed to explore the cause of this proliferative stimulation post-sevoflurane exposure using one of the most oncogenic genes, the KRAS mutation. The results of this study proved that sevoflurane certainly induced both ERK/MEK and PI3K/AKT signaling pathways, but this was not directly related to the KRAS mutations.

Free Research Field

麻酔学

Academic Significance and Societal Importance of the Research Achievements

担癌患者の安全な麻酔管理を達成するために必須の基礎的な理解を進めるため、本研究では消化器がん細胞株の麻酔薬暴露後の増殖影響を明らかにすることを目的とした。特に本研究では手術時間の長い消化器がんを取り上げ、特定の遺伝子変異と吸入麻酔薬による増殖変化について精査し、一部のタンパク質の活性化を見いだした。将来的にはがんの外科的処置の炎症を抑え、免疫を障害しない周術期管理を目指した基盤を整備し、より安全な麻酔薬の選択方法の提案や周術期管理を補完するものである。